- Report
- February 2024
- 70 Pages
Latin America
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Germany
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Italy
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Oman
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
France
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
United States
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Spain
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Iran
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Russia
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Australia
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
China
From €4226EUR$4,750USD£3,649GBP
- Report
- February 2024
- 70 Pages
Japan
From €4226EUR$4,750USD£3,649GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4226EUR$4,750USD£3,649GBP

Vildagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the amount of incretin hormones in the body. This helps to reduce blood sugar levels in people with type 2 diabetes. Vildagliptin is usually taken in combination with other diabetes medications, such as metformin or a sulfonylurea. It is also used to treat non-alcoholic fatty liver disease (NAFLD).
Vildagliptin is available in tablet form and is taken orally. It is generally well tolerated, with the most common side effects being nausea, diarrhea, and headache. It is important to note that vildagliptin can interact with other medications, so it is important to discuss all medications with a healthcare provider before taking vildagliptin.
Vildagliptin is marketed by several companies, including Novartis, Merck, and Boehringer Ingelheim. It is also available in generic form from several generic drug manufacturers. Show Less Read more